Published in Oncogene on May 18, 2015
PDK1 promotes tumor growth and metastasis in a spontaneous breast cancer model. Oncogene (2015) 0.82
Molecular Pathways: Targeting the PI3K Pathway in Cancer-BET Inhibitors to the Rescue. Clin Cancer Res (2016) 0.75
Endometrial cancer cells exhibit high expression of p110β and its selective inhibition induces variable responses on PI3K signaling, cell survival and proliferation. Oncotarget (2017) 0.75
High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A (2005) 6.62
Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature (2008) 6.04
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene (2008) 4.39
PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer (2011) 4.37
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
PI 3-kinase p110beta: a new target for antithrombotic therapy. Nat Med (2005) 3.96
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Mutation of the PIK3CA oncogene in human cancers. Br J Cancer (2006) 3.04
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res (2011) 2.81
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
Visualizing multidimensional cancer genomics data. Genome Med (2013) 2.19
Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol (2014) 1.95
Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends Biochem Sci (2007) 1.90
Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res (2014) 1.65
PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discov (2014) 1.58
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 1.42
Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer. ACS Med Chem Lett (2011) 1.24
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer. Proc Natl Acad Sci U S A (2014) 1.15
Retracted Erlotinib induces mitochondrial-mediated apoptosis in human H3255 non-small-cell lung cancer cells with epidermal growth factor receptorL858R mutation through mitochondrial oxidative phosphorylation-dependent activation of BAX and BAK. Mol Pharmacol (2008) 1.06
Targeting PI3 kinase in cancer. Pharmacol Ther (2014) 0.99
Erlotinib resistance in lung cancer: current progress and future perspectives. Front Pharmacol (2013) 0.88
Characterization of a tumor-associated activating mutation of the p110β PI 3-kinase. PLoS One (2013) 0.86
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. J Natl Compr Canc Netw (2014) 0.82
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat Med (2015) 1.41
Adaptive stress signaling in targeted cancer therapy resistance. Oncogene (2015) 1.07
IκΒα inhibits apoptosis at the outer mitochondrial membrane independently of NF-κB retention. EMBO J (2014) 0.80